Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
about
Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challengeEpstein-barr virus vaccines.High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes.Mapping of B-cell epitopes on the polypeptide chain of the Epstein-Barr virus major envelope glycoprotein and candidate vaccine molecule gp340.
P2860
Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Epstein-Barr virus (EBV) glyco ...... pendent cellular cytotoxicity.
@en
type
label
Epstein-Barr virus (EBV) glyco ...... pendent cellular cytotoxicity.
@en
prefLabel
Epstein-Barr virus (EBV) glyco ...... pendent cellular cytotoxicity.
@en
P2093
P2860
P1433
P1476
Epstein-Barr virus (EBV) glyco ...... ependent cellular cytotoxicity
@en
P2093
P2860
P304
P407
P577
1991-02-01T00:00:00Z